TABLE.
Case | Gender | Age | NFT Stage | Aβ Phase | APOE | AGD | TDP-43 | HS |
---|---|---|---|---|---|---|---|---|
1 | Female | 34 | I | 0 | 3/4 | 0 | 0 | 0 |
2 | Female | 55 | I | 0 | 3/3 | 0 | 0 | 0 |
3 | Male | 58 | I | 1 | 3/4 | 0 | 0 | 0 |
4 | Male | 60 | I | 1 | 3/3 | 0 | 0 | 0 |
5 | Male | 61 | I | 0 | 3/3 | 0 | 0 | 0 |
6 | Female | 65 | I | 0 | 3/4 | 0 | 0 | 0 |
7 | Male | 69 | I | 0 | 3/3 | 0 | 0 | 0 |
8 | Male | 82 | I | 0 | 3/4 | 0 | 0 | 0 |
9 | Male | 37 | II | 0 | 3/3 | 0 | 0 | 0 |
10 | Female | 48 | II | 0 | 3/3 | 0 | 0 | 0 |
11 | Male | 53 | II | 0 | 3/4 | 0 | 0 | + |
12 | Female | 56 | II | 0 | 3/4 | 0 | 0 | 0 |
13 | Male | 56 | II | 0 | 3/3 | 0 | 0 | 0 |
14 | Male | 56 | II | 0 | 3/3 | 0 | 0 | 0 |
15 | Male | 61 | II | 0 | 3/3 | 0 | 0 | 0 |
16 | Male | 61 | II | 0 | 3/3 | 0 | 0 | 0 |
17 | Male | 62 | II | 0 | 3/3 | 0 | 0 | 0 |
18 | Female | 62 | II | 0 | 3/3 | 0 | 0 | 0 |
19 | Male | 62 | II | 0 | 3/3 | 0 | 0 | 0 |
20 | Male | 62 | II | 2 | 3/4 | 0 | 0 | 0 |
21 | Female | 63 | II | 0 | 2/3 | 0 | 0 | 0 |
22 | Male | 64 | II | 0 | 3/3 | 0 | 0 | 0 |
23 | Male | 64 | II | 0 | 3/3 | 0 | 0 | + |
24 | Male | 64 | II | 1 | 3/4 | 0 | 0 | 0 |
25 | Male | 65 | II | 0 | 3/3 | 0 | 0 | 0 |
26 | Female | 82 | II | 1 | 3/3 | 0 | 0 | 0 |
27 | Male | 85 | II | 0 | 2/3 | 0 | 0 | 0 |
28 | Female | 86 | II | 2 | 3/3 | 0 | 0 | 0 |
29 | Female | 87 | II | 0 | 3/3 | 0 | 0 | 0 |
30 | Male | 87 | II | 2 | 3/4 | 0 | 0 | 0 |
31 | Male | 52 | III | 0 | 3/3 | 0 | 0 | 0 |
32 | Male | 55 | III | 1 | 3/4 | 0 | 0 | 0 |
33 | Female | 58 | III | 0 | 3/3 | 0 | + | 0 |
34 | Male | 66 | III | 0 | 2/3 | 0 | 0 | +++ |
35 | Female | 67 | III | 0 | 3/4 | 0 | 0 | 0 |
36 | Female | 68 | III | 3 | 3/4 | 0 | 0 | 0 |
37 | Female | 68 | III | 1 | 3/4 | 0 | 0 | 0 |
38 | Female | 68 | III | 2 | 3/4 | 0 | 0 | 0 |
39 | Male | 69 | III | 0 | 2/3 | 0 | 0 | + |
40 | Female | 69 | III | 5 | 4/4 | 0 | 0 | 0 |
41 | Female | 70 | III | 0 | 3/3 | 0 | 0 | 0 |
42 | Male | 71 | III | 0 | 3/3 | 0 | 0 | + |
43 | Male | 71 | III | 3 | 4/4 | 0 | 0 | 0 |
44 | Female | 76 | III | 1 | 3/3 | 0 | 0 | 0 |
45 | Female | 83 | III | 0 | 3/4 | 0 | 0 | 0 |
46 | Female | 86 | III | 3 | 3/4 | 0 | 0 | 0 |
47 | Female | 87 | III | 0 | 3/4 | 0 | 0 | 0 |
48 | Female | 88 | III | 0 | 2/3 | 0 | 0 | 0 |
49 | Female | 88 | III | 0 | 3/3 | 0 | 0 | + |
50 | Male | 89 | III | 0 | 3/3 | 0 | 0 | 0 |
51 | Female | 89 | III | 0 | 3/3 | 0 | +++ | +++ |
52 | Male | 91 | III | 0 | 3/3 | 0 | 0 | + |
53 | Male | 93 | III | 0 | 3/3 | 0 | 0 | 0 |
54 | Male | 71 | IV | 3 | 3/3 | 0 | 0 | 0 |
55 | Male | 72 | IV | 2 | 3/3 | 0 | 0 | 0 |
56 | Female | 75 | IV | 5 | 4/4 | 0 | 0 | 0 |
57 | Female | 78 | IV | 3 | 3/4 | 0 | 0 | 0 |
58 | Male | 83 | IV | 3 | 3/3 | 0 | 0 | 0 |
59 | Female | 84 | IV | 2 | 3/4 | 0 | 0 | 0 |
60 | Female | 84 | IV | 2 | 4/4 | 0 | 0 | ++ |
61 | Female | 86 | IV | 3 | 3/3 | 0 | 0 | 0 |
62 | Female | 86 | IV | 3 | 3/4 | 0 | +++ | + |
63 | Female | 89 | IV | 3 | 3/3 | 0 | 0 | 0 |
64 | Male | 90 | IV | 3 | 3/4 | 0 | 0 | 0 |
65 | Female | 55 | V | 5 | 3/3 | 0 | 0 | 0 |
66 | Male | 58 | V | 2 | 3/4 | 0 | 0 | 0 |
67 | Female | 72 | V | 4 | 3/3 | 0 | 0 | 0 |
68 | Female | 73 | V | 5 | 3/3 | 0 | 0 | 0 |
69 | Female | 75 | V | 2 | 4/4 | 0 | 0 | 0 |
70 | Female | 76 | V | 4 | 3/4 | 0 | 0 | 0 |
71 | Female | 78 | V | 4 | 3/3 | 0 | +++ | + |
72 | Female | 78 | V | 0 | 3/3 | 0 | 0 | ++ |
73 | Female | 78 | V | 3 | 3/3 | 0 | 0 | 0 |
74 | Male | 78 | V | 5 | 3/4 | 0 | 0 | + |
75 | Male | 80 | V | 2 | 3/3 | 0 | 0 | 0 |
76 | Female | 81 | V | 4 | 3/3 | 0 | 0 | 0 |
77 | Female | 82 | V | 3 | 3/3 | 0 | + | 0 |
78 | Male | 82 | V | 4 | 3/3 | 0 | 0 | 0 |
79 | Male | 84 | V | 3 | 3/4 | 0 | ++ | 0 |
80 | Female | 85 | V | 3 | 3/4 | 0 | 0 | + |
81 | Female | 87 | V | 4 | 2/4 | 0 | +++ | 0 |
82 | Female | 88 | V | 3 | 3/3 | 0 | 0 | 0 |
83 | Female | 88 | V | 5 | 3/3 | 0 | 0 | 0 |
84 | Male | 88 | V | 3 | 2/2 | 0 | 0 | 0 |
85 | Male | 88 | V | 4 | 2/3 | 0 | 0 | 0 |
86 | Male | 89 | V | 3 | 3/3 | 0 | 0 | 0 |
87 | Female | 89 | V | 4 | 3/3 | 0 | ++ | 0 |
88 | Female | 90 | V | 2 | 3/3 | 0 | 0 | 0 |
89 | Female | 92 | V | 4 | 3/3 | 0 | 0 | 0 |
90 | Male | 93 | V | 2 | 3/4 | 0 | 0 | +++ |
91 | Female | 96 | V | 5 | 3/3 | 0 | 0 | 0 |
92 | Female | 97 | V | 3 | 3/3 | 0 | 0 | 0 |
93 | Male | 75 | VI | 4 | 3/3 | 0 | 0 | 0 |
94 | Female | 83 | VI | 3 | 3/4 | 0 | +++ | + |
95 | Female | 85 | VI | 4 | 3/4 | 0 | ++ | + |
The cohort consisted of 52 females and 43 males (age range 34–97 ± 13.1 years of age; mean age 74.5 years).
Its composition reflects the fact that early neurofibrillary changes corresponding to NFT stages I–II are already present in the third and fourth decades of life. NFT stages and Aβ phases increase with age. The disease process underlying sporadic AD develops over a period of decades (11).
NFT, neurofibrillary tangle stages I–VI; Aβ, amyloid-β deposition phases 0–5; AGD, argyrophilic grain disease; HS, hippocampal sclerosis.